Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by 99942Apophison Sep 22, 2022 9:43am
289 Views
Post# 34978654

RE:Warrants Expiration Dates per Q2 M&D

RE:Warrants Expiration Dates per Q2 M&D99942Apophis wrote 
As of August 29, 2022, there were 64,759,165 warrants outstanding. Each whole warrant entitles the holder thereof to purchase one additional common share.
The warrants are exercisable as follows: 3,165,008 at a price of $0.50 until October 3, 2022, 4,095,157 at a price of $0.50 until January 9, 2023, and 57,499,000 at a price of $0.35 until August 22, 2024.

Chances are slim though possible that a NR of substance is released before October 3/2022 to capitalize that warrant exercise  more than likely the January 9/2023 will be taken up before it expires as another update will occur before then. So there is money in sight for the company.
<< Previous
Bullboard Posts
Next >>